Stay updated on FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial
Sign up to get notified when there's something new on the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page.

Latest updates to the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check9 days agoChange DetectedThe study record for the FIREFISH trial of risdiplam in infants with Type 1 spinal muscular atrophy is displayed, including its completed status, study methods and outcomes, eligibility criteria, publications, and supporting documents.SummaryDifference77%

- Check30 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study detail page now shows a 403 Forbidden message, replacing the expected content and preventing users from accessing FIREFISH trial information.SummaryDifference20%

- Check65 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, signaling a new version of the page. This change reflects an update to the page's metadata rather than the study content.SummaryDifference0.0%

Stay in the know with updates to FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page.